Latest Issue of Science News


News

Drug aids destruction of lymphoma cells

In the cancer called diffuse large B-cell lymphoma, certain white blood cells—B cells—in the

lymph tissues proliferate out of control. These malignant immune cells crowd out their healthy

comrades and impair a person's ability to fight disease. Standard chemotherapy sends this

lymphoma into remission only in 30 to 40 percent of patients.

Scientists in Europe now report that a drug called rituximab, or Rituxan, boosts the remission

rate significantly. The researchers treated more than 300 patients who had large B-cell

lymphoma, giving about half of them intravenous rituximab plus an infusion of four standard

chemotherapy drugs. The other patients received standard chemotherapy alone. Treated in

hospitals and clinics in France, Belgium, or Switzerland, all were between age 60 and 80. They

each received eight treatments over 6 weeks.

Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.

X
This article is available only to subscribing members. Join SSP today or Log in.